ClinicalTrials.gg
Not yet recruitingNCT07940803Updated Nov 17, 2026

A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes

A Phase 1/2 interventional study of NNC0662-3168 (Test product-A) and Placebo matched to NNC0662-3168 (Test product-A) in Overweight, Obesity and Type 2 Diabetes Mellitus, sponsored by Novo Nordisk A/S. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 1/2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Obesity by Novo Nordisk A/S — 50 open to participants now, 68 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Planned enrollment
55th of 168
300 · median 138
Started
2026
with 48 others
Phase 1/2
2 of 209
1 open now
Primary completion
2028-03
later than 39 of 67 live
Registered
208th of 209
by date

Among the 209 studies in Obesity by Novo Nordisk A/S, this one is the 55th largest by planned enrollment of the 168 interventional ones that give a count, is one of 49 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 39 of the 67 other live ones, and was the 208th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

50 of the 209 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

45 more — sign in →

By country, each count listing its studies:

All 50 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about NNC0662-3168 as a potential treatment for people living with overweight or obesity and/or type 2 diabetes(T2D). The study will investigate its safety, tolerability and its effects in the body. The study will be conducted in four parts. Part A: Single Ascending Dose, Part B: Multiple Ascending Dose: Part C: Dose-finding in Weight Management. Part D: T2D proof-of-concept.

03

Conditions studied

  • Overweight
  • Obesity
  • Type 2 Diabetes Mellitus

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 300 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female (sex at birth).

  • Age at the time of signing the :
  • For Part A: 18-55 years (both inclusive).
  • For Part B: 18-55 years (both inclusive).
  • For Part C: 18-65 years (both inclusive).
  • For Part D: 18-75 years (both inclusive).

Part D :

  • Diagnosed with type 2 diabetes mellitus >= 120 days before screening.
  • Treatment-naive to antidiabetic drugs, or on stable daily dose(s) >= 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
  • (HbA1c) of 7.0-10.0% (53-86 millimoles per mole (mmol/mol) (both inclusive) at screening.
  • Able and willing to adhere to the protocol, including wearing the study CGM provided by Novo Nordisk, as judged by the investigator.
  • Other protocol-defined inclusion criteria also apply.

Exclusion criteria

Exclusion Criteria:

  • Any body weight change (≥ 5% self-reported change) or dieting attempts (e.g., participation in a weight-reduction program) within 90 days before screeninga.
  • Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening.
  • Treatment with any compound containing GLP-1, GIP or amylin receptor agonism within 90 days before screening.
  • 2nd or 3rd degree atrioventricular-block, prolongation of the QRS complex over 120 ms, or of the interval by Fridericia (QTcF) calculation over 450 ms (females) or 430 ms (males), or any other clinically significant abnormal results as judged by the investigator, at screening.
  • History of type 1 diabetes mellitus in all partsa
  • For Parts A, B and C: History of type 2 diabetes mellitusa
  • For Parts A, B and C: ≥ 6.5% (48 mmol/mol) at screening
  • Calcitonin ≥ 50 ng/L at screening.

For Part D:

- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    NNC0662-3168 (Test product-A)

    Participants will receive NNC0662-3168 by subcutaneous injection in Part A to Part D.

    Drug: NNC0662-3168 (Test product-A)

  • Placebo comparator
    Placebo matched to NNC0662-3168 (Test product-A)

    Participants will receive placebo by subcutaneous injection in Part A to Part C.

    Drug: Placebo matched to NNC0662-3168 (Test product-A)

  • Active comparator
    Product-B

    Participants will receive active comparator (product-B) by subcutaneous injection in Part C to Part D.

    Drug: Active Comparator (Product-B)

Interventions

  • DrugNNC0662-3168 (Test product-A)

    NNC0662-3168 is administered subcutaneously.

  • DrugPlacebo matched to NNC0662-3168 (Test product-A)

    Placebo is administered subcutaneously.

  • DrugActive Comparator (Product-B)

    Active Comparator is administered subcutaneously.

07

What researchers measure

Primary outcomes

  1. Part A: Number of treatment-emergent adverse events (TEAEs)

    Number of events.

    Time frame: From dosing on day 1 upto 29 days

  2. Part B: Number of treatment-emergent adverse events (TEAEs)

    Number of events.

    Time frame: From dosing at week 0 up to 39 weeks

  3. Part C: Change in body weight

    Measure in Percentage (%) change in body weight

    Time frame: From baseline (week 0) to week 36

  4. Part D: Change in glycated haemoglobin (HbA1c)

    Measured in percentage of glycated haemoglobin.

    Time frame: From baseline (week 0) to week 28

Secondary outcomes

  1. Part A: Area under the NNC0662-3168 concentration-time curve

    Measured in hours times nanomole per litre ( h\*nmol/L).

    Time frame: From pre-dose on day 1 upto 29 days

  2. Part A: Maximum concentration of NNC0662-3168

    Measured in nanomole per litre (nmol/L).

    Time frame: From pre-dose on day 1 upto 29 days

  3. Part B: Area under the NNC0662-3168 concentration-time curve

    Measured in h\*nmol/L.

    Time frame: From pre dose on day 1 upto 39 weeks

  4. Part B: Maximum concentration of NNC0662-3168

    Measured in nmol/L.

    Time frame: From pre-dose on day 1 upto 39 weeks

  5. Part C: Change in body weight (%)

    Measured in percentage change in body weight

    Time frame: From baseline (week 0) to week 36

  6. Part C: Change in body weight (Kg)

    Measured in kilogram

    Time frame: From baseline to week 36

  7. Part C: Body weight reduction greater than or equals to (≥) 5% (Yes/No)

    Measured in Count of participants.

    Time frame: From baseline (week 0) to week 36

  8. Part C: Body weight reduction greater than or equals to (≥) 10% (Yes/No)

    Measured in Count of participants.

    Time frame: From baseline (week 0) to week 36

  9. Part C : Body weight reduction greater than or equals to (≥) 15% (Yes/No)

    Measured in Count of participants.

    Time frame: From baseline (week 0) to week 36

  10. Part C: Body weight reduction greater than or equals to (≥) 20% (Yes/No)

    Measured in Count of participants.

    Time frame: From baseline (week 0) to week 36

  11. Part C: Body weight reduction greater than or equals to (≥) 25% (Yes/No)

    Measured in Count of participants.

    Time frame: From baseline (week 0) to week 36

  12. Part C: Number of treatment-emergent adverse events (TEAEs)

    Number of events.

    Time frame: From dosing at week 0 to week 43

  13. Part D: Change in fasting plasma glucose (FPG)

    Measured in millimoles per litre (mmol/L).

    Time frame: From baseline (week 0) to week 28

  14. Part D: Change in homeostatic model assessment of insulin resistance (HOMA-IR)

    Time frame: From baseline (week 0) to week 28

  15. Part D: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)

    Measured in percentage points.

    Time frame: From baseline (week -2 to week 0) to (week 26 to week 28)

  16. Part D: Number of treatment-emergent adverse events (TEAEs)

    Number of events.

    Time frame: From dosing at week 0 to week 35

08

Study locations

2 sites
  • Celerion, Phoenix
    Tempe, Arizona 85283, United States
  • Celerion, Lincoln
    Lincoln, Nebraska 68502, United States
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2028, 16 months later.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 13, 2026
Primary completionEst.
Mar 25, 2028
CompletionEst.
Mar 25, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07940803
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 13, 2026 (estimated)
Primary completion
Mar 25, 2028 (estimated)
Completion
Mar 25, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion